AAPG Stock Forecast & Price Target

Ascentage Pharma Group has demonstrated significant commercial momentum, as evidenced by olverembatinib's impressive sales growth of approximately 93% year-over-year, reaching around US$30.3 million in the first half of 2025 and surpassing $100 million in cumulative sales since its launch. The company has also expanded its market reach substantially, with formulary coverage extending to over 295 hospitals, representing a 47% year-over-year increase, and a comprehensive distribution network involving approximately 867 hospitals and 290 distributors, alongside a notable 17% growth in onboarded direct-to-patient pharmacies. Furthermore, the positive trend in capital formation for mid-cap biotech firms and the overall strong performance of biotech in the Chinese market, as indicated by a 58% increase in a Biotech ETF, underscores a favorable environment for Ascentage Pharma's ongoing growth and potential.

Ascentage Pharma Group faces substantial challenges due to a volume-based procurement program that pressures revenue growth and may impact profit margins, particularly as aggressive NRDL repricing cycles are anticipated. The company's underperformance in critical clinical trials, notably the failure to meet primary endpoints in pivotal studies, raises concerns about its ability to expand globally and compete effectively in the market. Additionally, the slower adoption of its product Olverembatinib in China, coupled with a lack of differentiation from existing therapies, contributes to a negative outlook for future growth and profitability.